|Bid||192.60 x 6700|
|Ask||192.65 x 11200|
|Day's Range||191.75 - 196.45|
|52 Week Range||121.25 - 207.90|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||30.67|
|Earnings Date||Nov. 11, 2021|
|Forward Dividend & Yield||1.40 (0.73%)|
|Ex-Dividend Date||Apr. 26, 2021|
|1y Target Est||199.50|
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
FRANKFURT (Reuters) -European companies playing key supporting roles in COVID-19 vaccine manufacturing are working to move production and supply chains closer to their customers to guard against trade restrictions that have interrupted supplies during the pandemic. Germany's Merck KGaA, whose Life Science unit is one of the world's largest makers of bioreactor gear and supplies, told Reuters it is pushing to spread its production network geographically so that fewer shipments have to cross customs borders. U.S. regulations in particular, which give priority to companies fulfilling U.S. government contracts, have posed a challenge for Merck as its seeks to meet soaring demand for supplies such as sterile fermentation bags and filters.
Germany's Merck KGaA on Thursday issued a more ambitious medium-term growth forecast for its Life Science unit, as manufacturers of COVID-19 vaccines and treatments snap up its materials and gear. Life Science division revenues are now expected to grow 7% to 10% per year until 2025, excluding the effect of currencies and acquisitions, significantly above market growth and higher than a previous goal of 6% to 9%, the diversified company said. "Life Science will sharpen its focus on the Asia-Pacific region, especially China, as well as on innovations and digital solutions in all businesses," the company said in a statement on its capital markets day on Thursday.